Big Pharma Giant Merck Partners With Psychedelic Research Company Novamind
Pharmaceutical giant Merck is partnering with psychedelic research company Novamind to test a possible therapy for treatment-resistant depression.
Pharmaceutical giant Merck is partnering with psychedelic research company Novamind to test a possible therapy for treatment-resistant depression.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.